Pharsight

1. List of Airduo Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782551 (Pediatric)	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Feb, 2036 (13 years from now)
US9782550 (Pediatric)	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Feb, 2036 (13 years from now)
US10918816 (Pediatric)	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Jun, 2036 (13 years from now)
US10569034	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
M	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

2. List of Amvuttra drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10208307	ALNYLAM PHARMS INC	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases	Jul, 2036 (13 years from now)
US11286486	ALNYLAM PHARMS INC	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases	Jul, 2036 (13 years from now)
US10683501	ALNYLAM PHARMS INC	Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases	Jul, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 13, 2027

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
25MG/0.5ML (25MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription

3. List of Armonair Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9782550 (Pediatric)	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Feb, 2036 (13 years from now)
US9782551 (Pediatric)	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Feb, 2036 (13 years from now)
US10918816 (Pediatric)	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Jun, 2036 (13 years from now)
US10569034	TEVA PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Jul 9, 2024
New Strength (NS)	Jul 9, 2024
Pediatric Exclusivity (PED)	Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH	POWDER;INHALATION	Discontinued
0.113MG/INH	POWDER;INHALATION	Discontinued
0.232MG/INH	POWDER;INHALATION	Discontinued
0.03MG/INH	POWDER;INHALATION	Discontinued

4. List of Austedo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10959996	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (13 years from now)
US11357772	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (13 years from now)
US11446291	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (13 years from now)
US10959996 (Pediatric)	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Sep, 2036 (13 years from now)
US11357772 (Pediatric)	TEVA BRANDED PHARM	Methods for the treatment of abnormal involuntary movement disorders	Sep, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Apr 3, 2024
New Chemical Entity Exclusivity (NCE)	Apr 3, 2022
M	Jun 24, 2024
Pediatric Exclusivity (PED)	Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 03 April, 2017

Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
6 mg, 9 mg and 12 mg	05 Apr, 2021	2		07 Mar, 2036

Strength	Dosage	Availability
6MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
12MG	TABLET;ORAL	Prescription

5. List of Balversa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10898482	JANSSEN BIOTECH	Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine	Feb, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 12, 2024

Drugs and Companies using ERDAFITINIB ingredient

NCE-1 date: April, 2023

Market Authorisation Date: 12 April, 2019

Treatment: Treatment of adults with locally advanced or metastatic, surgically unresectable urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription

6. List of Baqsimi drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213487	ELI LILLY AND CO	Nasal powder formulation for treatment of hypoglycemia	Feb, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Jul 24, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 24 July, 2019

Treatment: Treatment of severe hypoglycemia in patients with diabetes

Dosage: POWDER;NASAL

Strength	Dosage	Availability
3MG	POWDER;NASAL	Prescription

7. List of Biktarvy drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10548846	GILEAD SCIENCES INC	Therapeutic compositions for treatment of human immunodeficiency virus	Nov, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jun 18, 2026
New Chemical Entity Exclusivity (NCE)	Feb 7, 2023
New Patient Population (NPP)	Jun 18, 2022
M	Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 07 February, 2018

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
50 mg/200 mg/ 25 mg	07 Feb, 2022	3		08 Nov, 2036

Strength	Dosage	Availability
EQ 30MG BASE;120MG;EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE	TABLET;ORAL	Prescription

8. List of Brilinta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300065	ASTRAZENECA	Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction	Jan, 2036 (12 years from now)
US10300065 (Pediatric)	ASTRAZENECA	Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction	Jul, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Nov 5, 2023
M	May 9, 2025
Pediatric Exclusivity (PED)	Nov 28, 2023

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
90 mg	20 Jul, 2015	16	04 Sep, 2018	17 Apr, 2030	Eligible
60 mg	30 Sep, 2015	3	04 Sep, 2018	17 Apr, 2030	Eligible

Strength	Dosage	Availability
60MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription

9. List of Calquence drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9796721	ASTRAZENECA	Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide	Jul, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10167291	ASTRAZENECA	Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide	Jul, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 21, 2026
New Chemical Entity Exclusivity (NCE)	Oct 31, 2022
New Indication (I)	Nov 21, 2022

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with small lymphocytic leukemia; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg	01 Nov, 2021	5		01 Jul, 2036

Strength	Dosage	Availability
100MG	CAPSULE;ORAL	Prescription

10. List of Calquence drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11059829	ASTRAZENECA	Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate	Jul, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with small lymphocytic leukemia; Treatment of adult patients with chronic lymphocytic leukemia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	TABLET;ORAL	Prescription

11. List of Carospir drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10493083	CMP DEV LLC	Spironolactone aqueous compositions	Oct, 2036 (13 years from now)
US11395828	CMP DEV LLC	Spironolactone aqueous compositions	Oct, 2036 (13 years from now)
US11389461	CMP DEV LLC	Spironolactone aqueous compositions	Oct, 2036 (13 years from now)
US10624906	CMP DEV LLC	Spironolactone aqueous compositions	Oct, 2036 (13 years from now)
US10888570	CMP DEV LLC	Spironolactone aqueous compositions	Oct, 2036 (13 years from now)
US9757394	CMP DEV LLC	Spironolactone aqueous formulations	Oct, 2036 (13 years from now)
US10660907	CMP DEV LLC	Spironolactone aqueous compositions	Oct, 2036 (13 years from now)
US11491166	CMP DEV LLC	Spironolactone aqueous compositions	Oct, 2036 (13 years from now)

Drugs and Companies using SPIRONOLACTONE ingredient

Market Authorisation Date: 04 August, 2017

Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; Carospir is indicated as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents; Carospir is indicated for the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction

Dosage: SUSPENSION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg/5 mL	31 Dec, 2020	1		28 Oct, 2036

Strength	Dosage	Availability
25MG/5ML	SUSPENSION;ORAL	Prescription

12. List of Cotellic drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10478400	GENENTECH INC	Immediate-release tablets containing combimetinib and methods of making and using the same	Jun, 2036 (13 years from now)
US11254649	GENENTECH INC	Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone	Jun, 2036 (13 years from now)
US10590102	GENENTECH INC	Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone	Jun, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478400 (Pediatric)	GENENTECH INC	Immediate-release tablets containing combimetinib and methods of making and using the same	Dec, 2036 (13 years from now)
US11254649 (Pediatric)	GENENTECH INC	Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone	Dec, 2036 (13 years from now)
US10590102 (Pediatric)	GENENTECH INC	Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone	Dec, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 10, 2022
New Indication (I)	Oct 28, 2025
M	Jul 28, 2025
Pediatric Exclusivity (PED)	Jan 28, 2026

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Market Authorisation Date: 10 November, 2015

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription

13. List of Cyclophosphamide drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10993952	INGENUS PHARMS LLC	Stable ready to use cyclophosphamide liquid formulations	Feb, 2036 (13 years from now)

Drugs and Companies using CYCLOPHOSPHAMIDE ingredient

Market Authorisation Date: 30 July, 2020

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
500 mg/2.5 mL and 1 g/5 mL	07 Mar, 2022	1		15 Feb, 2036

Strength	Dosage	Availability
1GM/5ML (200MG/ML)	SOLUTION;INTRAVENOUS	Prescription
2GM/10ML (200MG/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG/2.5ML (200MG/ML)	SOLUTION;INTRAVENOUS	Prescription

14. List of Cysview Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311620	PHOTOCURE ASA	Neoadjuvant therapy for bladder cancer	Dec, 2036 (13 years from now)
US10556010	PHOTOCURE ASA	Neoadjuvant therapy for bladder cancer	Dec, 2036 (13 years from now)

Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2010

Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy

Dosage: FOR SOLUTION;INTRAVESICAL

Strength	Dosage	Availability
100MG/VIAL	FOR SOLUTION;INTRAVESICAL	Prescription

15. List of Daurismo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10414748	PFIZER	Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate	Apr, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11168066	PFIZER	Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 21, 2023
Orphan Drug Exclusivity (ODE)	Nov 21, 2025

Drugs and Companies using GLASDEGIB MALEATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription

16. List of Delstrigo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842751	MSD MERCK CO	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine	Nov, 2036 (13 years from now)
US10603282	MSD MERCK CO	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine	Nov, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 30, 2023
New Indication (I)	Sep 19, 2022
New Patient Population (NPP)	Jan 27, 2025

Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 30 August, 2018

Treatment: NA

Dosage: TABLET;ORAL

17. List of Dexmedetomidine Hydrochloride drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717796	HQ SPCLT PHARMA	Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container	Apr, 2036 (13 years from now)
US9649296	HQ SPCLT PHARMA	Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container	Apr, 2036 (13 years from now)

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 October, 2015

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

18. List of Duobrii drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10426787	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (13 years from now)
US10251895	BAUSCH	Topical compositions and methods for treating psoriasis	Jun, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Apr 25, 2022

Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

19. List of Elyxyb drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376527	BDSI	Oral composition of celecoxib for treatment of pain	May, 2036 (13 years from now)
US10722456	BDSI	Oral composition of celecoxib for treatment of pain	May, 2036 (13 years from now)
US10799517	BDSI	Oral composition of celecoxib for treatment of pain	May, 2036 (13 years from now)
US9949990	BDSI	Oral composition of celecoxib for treatment of pain	May, 2036 (13 years from now)
US9795620	BDSI	Oral composition of celecoxib for treatment of pain	May, 2036 (13 years from now)
US9572819	BDSI	Oral composition of celecoxib for treatment of pain	May, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	May 5, 2023

Drugs and Companies using CELECOXIB ingredient

Market Authorisation Date: 05 May, 2020

Treatment: Acute treatment of migraine with or without aura in adults

Dosage: SOLUTION;ORAL

20. List of Entresto drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11058667	NOVARTIS PHARMS CORP	Sacubitril-valsartan dosage regimen for treating heart failure	May, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Oct 1, 2022
M	Feb 16, 2024
Pediatric Exclusivity (PED)	Apr 1, 2023

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 07 July, 2015

Treatment: Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb or previously taking low doses of these agents, by titrating up from half the usually recommended starting dose

Dosage: TABLET;ORAL

21. List of Epaned drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10772868	AZURITY	Enalapril formulations	Mar, 2036 (13 years from now)
US9669008	AZURITY	Enalapril formulations	Mar, 2036 (13 years from now)
US10786482	AZURITY	Enalapril formulations	Mar, 2036 (13 years from now)
US10154987	AZURITY	Enalapril formulations	Mar, 2036 (13 years from now)
US9808442	AZURITY	Enalapril formulations	Mar, 2036 (13 years from now)
US10039745	AZURITY	Enalapril formulations	Mar, 2036 (13 years from now)
US11141405	AZURITY	Enalapril formulations	Mar, 2036 (13 years from now)
US11040023	AZURITY	Enalapril formulations	Mar, 2036 (13 years from now)
US11173141	AZURITY	Enalapril formulations	Mar, 2036 (13 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: Treatment of hypertension; Method of treating left ventricular dysfunction; Method of treating hypertension; Method of treatment of heart failure; Treatment of heart failure

Dosage: SOLUTION;ORAL

22. List of Esomeprazole Magnesium drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835488	DEXCEL PHARMA	Stable orally disintegrating pharmaceutical compositions	Dec, 2036 (13 years from now)
US10076494	DEXCEL PHARMA	Stable orally disintegrating pharmaceutical compositions	Dec, 2036 (13 years from now)

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient

Market Authorisation Date: 20 October, 2020

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

23. List of Exem Foam Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9849199	GISKIT	Composition and method for medical imaging of body cavities	Feb, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 7, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: NA

Dosage: FOAM;INTRAUTERINE

24. List of Ezallor Sprinkle drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413543	SUN PHARM	Stable multiparticulate pharmaceutical composition of rosuvastatin	Feb, 2036 (13 years from now)

Drugs and Companies using ROSUVASTATIN CALCIUM ingredient

Market Authorisation Date: 18 December, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

25. List of Fintepla drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10947183	ZOGENIX INC	Fenfluramine compositions and methods of preparing the same	Dec, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10950331 (Pediatric)	ZOGENIX INC	Control system for control of distribution of medication	Mar, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jun 25, 2027
New Product (NP)	Jun 25, 2023
New Indication (I)	Mar 25, 2025
Pediatric Exclusivity (PED)	Dec 25, 2027

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 June, 2020

Treatment: NA

Dosage: SOLUTION;ORAL

26. List of Fyarro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10705070	AADI	Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug	Mar, 2036 (13 years from now)
US10973806	AADI	Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin	Jun, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Nov 22, 2024

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered on days 1 and 8 of a 21-day cycle

Dosage: POWDER;INTRAVENOUS

27. List of Gavreto drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10030005	GENENTECH INC	Inhibitors of RET	Nov, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 4, 2025
Orphan Drug Exclusivity (ODE)	Sep 4, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: September, 2024

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate); Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy

Dosage: CAPSULE;ORAL

28. List of Genosyl drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213572	VERO BIOTECH	Nitrogen dioxide storage cassette	Feb, 2036 (13 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS;INHALATION

29. List of Gloperba drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10383821	ROMEG	Colchicine drug-to-drug interactions	Nov, 2036 (13 years from now)
US10383820	ROMEG	Colchicine drug-to-drug interactions	Nov, 2036 (13 years from now)
US9907751	ROMEG	Composition and method of use of colchicine oral liquid	Nov, 2036 (13 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 30 January, 2019

Treatment: A method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution

Dosage: SOLUTION;ORAL

30. List of Gvoke Hypopen drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649364	XERIS	Methods for producing stable therapeutic formulations in aprotic polar solvents	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Sep 10, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 10 September, 2019

Treatment: Treatment of severe hypoglycemia

Dosage: SOLUTION;SUBCUTANEOUS

31. List of Ibrance drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11065250	PFIZER	Solid dosage forms of palbociclib	May, 2036 (13 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Market Authorisation Date: 01 November, 2019

Treatment: NA

Dosage: TABLET;ORAL

32. List of Imbruvica drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828259	PHARMACYCLICS INC	Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor	Mar, 2036 (13 years from now)
US9655857	PHARMACYCLICS INC	Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor	Mar, 2036 (13 years from now)
US10010507	PHARMACYCLICS INC	Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor	Mar, 2036 (13 years from now)
US10213386	PHARMACYCLICS INC	Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor	Mar, 2036 (13 years from now)
US10213386 (Pediatric)	PHARMACYCLICS INC	Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor	Sep, 2036 (13 years from now)
US10010507 (Pediatric)	PHARMACYCLICS INC	Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor	Sep, 2036 (13 years from now)
US9655857 (Pediatric)	PHARMACYCLICS INC	Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor	Sep, 2036 (13 years from now)
US10828259 (Pediatric)	PHARMACYCLICS INC	Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor	Sep, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
M	Jan 25, 2022
New Patient Population (NPP)	Aug 24, 2025
Pediatric Exclusivity (PED)	Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 16 February, 2018

Treatment: NA

Dosage: TABLET;ORAL

33. List of Ingrezza drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10851104	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10851103	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10844058	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10065952	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10906902	NEUROCRINE	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)	Dec, 2036 (13 years from now)
US10919892	NEUROCRINE	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)	Dec, 2036 (13 years from now)
US10906903	NEUROCRINE	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)	Dec, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

34. List of Inomax drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770570	MALLINCKRODT HOSP	Apparatus and method for monitoring nitric oxide delivery	May, 2036 (13 years from now)
US9770570 (Pediatric)	MALLINCKRODT HOSP	Apparatus and method for monitoring nitric oxide delivery	Nov, 2036 (13 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitiric oxide as compared to the desired delivery concentration of nitric oxide

Dosage: GAS;INHALATION

35. List of Invega Hafyera drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143693	JANSSEN PHARMS	Dosing regimen for missed doses for long-acting injectable paliperidone esters	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Strength (NS)	Aug 30, 2024

Drugs and Companies using PALIPERIDONE PALMITATE ingredient

Market Authorisation Date: 18 May, 2015

Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

36. List of Kisqali drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799506	NOVARTIS	Ribociclib tablet	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 13, 2022
New Patient Population (NPP)	Dec 10, 2024

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: NA

Dosage: TABLET;ORAL

37. List of Kisqali Femara Co-pack (copackaged) drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799506	NOVARTIS	Ribociclib tablet	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 13, 2022
New Patient Population (NPP)	Dec 10, 2024

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: NA

Dosage: TABLET;ORAL

38. List of Korlym drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10660904	CORCEPT THERAP	Optimizing mifepristone levels for cushing's patients	Apr, 2036 (13 years from now)
US10166243	CORCEPT THERAP	Optimizing mifepristone levels for cushing'S patients	Apr, 2036 (13 years from now)
US10166242	CORCEPT THERAP	Optimizing mifepristone levels for Cushing's patients	Apr, 2036 (13 years from now)
US9943526	CORCEPT THERAP	Optimizing mifepristone levels for cushing's patients	Apr, 2036 (13 years from now)
US10006924	CORCEPT THERAP	Method for differentially diagnosing ACTH-dependent cushing's syndrome	Aug, 2036 (13 years from now)
US10495650	CORCEPT THERAP	Method for differentially diagnosing ACTH-dependent Cushing's syndrome	Aug, 2036 (13 years from now)
US9829495	CORCEPT THERAP	Method for differentially diagnosing ACTH-dependent Cushing's syndrome	Aug, 2036 (13 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

39. List of Kynmobi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10449146	SUNOVION PHARMS INC	Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa	Apr, 2036 (13 years from now)
US10959943	SUNOVION PHARMS INC	Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

40. List of Lansoprazole drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077055	DEXCEL PHARMA	Orally disintegrating compositions	Apr, 2036 (13 years from now)

Drugs and Companies using LANSOPRAZOLE ingredient

Market Authorisation Date: 07 June, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

41. List of Leqvio drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10851377	NOVARTIS	Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder	Aug, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

42. List of Levothyroxine Sodium drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154498	CUSTOPHARM INC	Stabilized liquid formulation of levothyroxine	Jul, 2036 (13 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 17 May, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

43. List of Levothyroxine Sodium drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11135190	FRESENIUS KABI USA	Levothyroxine liquid formulations	Dec, 2036 (13 years from now)
US9782376	FRESENIUS KABI USA	Levothyroxine liquid formulations	Dec, 2036 (13 years from now)
US10398669	FRESENIUS KABI USA	Levothyroxine liquid formulations	Dec, 2036 (13 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 11 April, 2019

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

44. List of Lexette drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020407	MAYNE PHARMA	Corticosteroid containing foam compositions and method of manufacture thereof	Nov, 2036 (13 years from now)
US10857159	MAYNE PHARMA	Halobetasol foam composition and method of use thereof	Nov, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Aug 18, 2024

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 24 May, 2018

Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older

Dosage: AEROSOL, FOAM;TOPICAL

45. List of Lonhala Magnair Kit drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688518	SUNOVION RESP	Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator	Nov, 2036 (13 years from now)
US10744277	SUNOVION RESP	Aerosol delivery device and method of operating the aerosol delivery device	Dec, 2036 (13 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: A method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

46. List of Lorbrena drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10420749	PFIZER	Crystalline form of lorlatinib free base	Jul, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020376	PFIZER	Crystalline form of lorlatinib free base	Jul, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 2, 2023
Orphan Drug Exclusivity (ODE)	Mar 3, 2028
New Indication (I)	Mar 3, 2024

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; Or alectinib, or ceritinib as first alk inhibitor for metastatic disease.; Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test

Dosage: TABLET;ORAL

47. List of Lotemax Sm drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596107	BAUSCH AND LOMB INC	Ophthalmic suspension composition	Dec, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Strength (NS)	Feb 22, 2022

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Market Authorisation Date: 22 February, 2019

Treatment: Treatment of post-operative inflammation and pain following ocular surgery

Dosage: GEL;OPHTHALMIC

48. List of Lytgobi drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10434103	TAIHO ONCOLOGY	Crystal of 3,5-disubstituted benzene alkynyl compound	Mar, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 30, 2027

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 30 September, 2022

Treatment: NA

Dosage: TABLET;ORAL

49. List of Makena drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11304962	COVIS	Methods of reducing risk of preterm birth	May, 2036 (13 years from now)
US10471075	COVIS	Methods of reducing risk of preterm birth	May, 2036 (13 years from now)
US11154562	COVIS	Methods of reducing risk of preterm birth	May, 2036 (13 years from now)
US9844558	COVIS	Methods of reducing risk of preterm birth	May, 2036 (13 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 03 February, 2011

Treatment: Reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

50. List of Mavyret drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11246866	ABBVIE INC	Solid pharmaceutical compositions for treating HCV	Jun, 2036 (13 years from now)
US11246866 (Pediatric)	ABBVIE INC	Solid pharmaceutical compositions for treating HCV	Dec, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 3, 2022
New Patient Population (NPP)	Apr 30, 2022
Orphan Drug Exclusivity (ODE)	Jun 10, 2028
New Dosing Schedule (D)	Sep 26, 2022
M	Apr 10, 2023
Pediatric Exclusivity (PED)	Feb 3, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: TABLET;ORAL

51. List of Minolira drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103517	EPI HLTH	Pharmaceutical compositions for minocycline	Apr, 2036 (13 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 May, 2017

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

52. List of Mounjaro drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9474780	ELI LILLY AND CO	GIP and GLP-1 co-agonist compounds	Jan, 2036 (12 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 13 May, 2022

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

53. List of Mycapssa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11338011	AMRYT	Method of treating diseases	Feb, 2036 (13 years from now)
US11052126	AMRYT	Method of treating diseases	Feb, 2036 (13 years from now)
US10695397	AMRYT	Method of treating diseases	Feb, 2036 (13 years from now)
US10238709	AMRYT	Method of treating diseases	Feb, 2036 (13 years from now)
US11510963	AMRYT	Method of treating diseases	Feb, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Jun 26, 2023

Drugs and Companies using OCTREOTIDE ACETATE ingredient

Market Authorisation Date: 26 June, 2020

Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide

Dosage: CAPSULE, DELAYED RELEASE;ORAL

54. List of Myrbetriq Granules drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10058536	APGDI	Pharmaceutical composition containing mirabegron	Mar, 2036 (13 years from now)
US10058536 (Pediatric)	APGDI	Pharmaceutical composition containing mirabegron	Oct, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Mar 25, 2024
Pediatric Exclusivity (PED)	Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 25 March, 2021

Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

55. List of Nexlizet drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912751	ESPERION THERAPS INC	Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease	Mar, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 21, 2025
New Product (NP)	Feb 26, 2023

Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: A method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoic acid and 10 mg ezetimibe

Dosage: TABLET;ORAL

56. List of Nubeqa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10010530	BAYER HEALTHCARE	Carboxamide derivative and its diastereomers in stable crystalline form	Jan, 2036 (12 years from now)
US10383853	BAYER HEALTHCARE	Carboxamide derivative and its diastereomers in stable crystalline form	Jan, 2036 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835515	BAYER HEALTHCARE	Carboxamide derivative and its diastereomers in stable crystalline form	Jan, 2036 (12 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 30, 2024
New Indication (I)	Aug 5, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

57. List of Ocaliva drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10751349	INTERCEPT PHARMS INC	Compositions of obeticholic acid and methods of use	Apr, 2036 (13 years from now)
US10052337	INTERCEPT PHARMS INC	Compositions of obeticholic acid and methods of use	Apr, 2036 (13 years from now)
US10758549	INTERCEPT PHARMS INC	Compositions of obeticholic acid and methods of use	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	May 27, 2023

Drugs and Companies using OBETICHOLIC ACID ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as monotherapy in adults unable to tolerate udca

Dosage: TABLET;ORAL

58. List of Odomzo drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10266523	SUN PHARM	Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof	Mar, 2036 (13 years from now)

Drugs and Companies using SONIDEGIB PHOSPHATE ingredient

Market Authorisation Date: 24 July, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

59. List of Omeprazole drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835488	DEXCEL PHARMA	Stable orally disintegrating pharmaceutical compositions	Dec, 2036 (13 years from now)
US10076494	DEXCEL PHARMA	Stable orally disintegrating pharmaceutical compositions	Dec, 2036 (13 years from now)

Drugs and Companies using OMEPRAZOLE ingredient

Market Authorisation Date: 05 July, 2017

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

60. List of Onivyde drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10456360	IPSEN INC	Stabilizing camptothecin pharmaceutical compositions	Oct, 2036 (13 years from now)
US10993914	IPSEN INC	Stabilizing camptothecin pharmaceutical compositions	Oct, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Oct 22, 2022

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2015

Treatment: NA

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

61. List of Orgovyx drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350170	MYOVANT SCIENCES	Solid preparation	Feb, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 18 December, 2020

Treatment: NA

Dosage: TABLET;ORAL

62. List of Orilissa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10682351	ABBVIE INC	Methods of administering elagolix	Sep, 2036 (13 years from now)
US10537572	ABBVIE INC	Methods of administering elagolix	Sep, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin

Dosage: TABLET;ORAL

63. List of Ortikos drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10172802	SUN PHARM INDS INC	Oral pharmaceutical dosage forms of budesonide	Sep, 2036 (13 years from now)
US9707182	SUN PHARM INDS INC	Oral pharmaceutical dosage forms of budesonide	Sep, 2036 (13 years from now)

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 13 June, 2019

Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

64. List of Oxbryta drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020382	GLOBAL BLOOD THERAPS	Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde	Dec, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 25, 2024

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 17 December, 2021

Treatment: Treating sickle cell disease by administering 1500 mg of voxelotor orally once daily; Increasing hemoglobin to treat sickle cell disease by administering 1500 mg of voxelotor orally once daily

Dosage: TABLET, FOR SUSPENSION;ORAL

65. List of Proair Digihaler drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10569034	TEVA BRANDED PHARM	Compliance monitoring module for a breath-actuated inhaler	Aug, 2036 (13 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

66. List of Procysbi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10328037	HORIZON	Methods for storing cysteamine formulations and related methods of treatment	Aug, 2036 (13 years from now)
US10548859	HORIZON	Methods for storing Cysteamine formulations and related methods of treatment	Aug, 2036 (13 years from now)
US10905662	HORIZON	Methods for storing cysteamine formulations and related methods of treatment	Aug, 2036 (13 years from now)
US10143665	HORIZON	Methods for storing cysteamine formulations and related methods of treatment	Aug, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 22, 2024
Pediatric Exclusivity (PED)	Feb 14, 2023

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 30 April, 2013

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: CAPSULE, DELAYED RELEASE;ORAL

67. List of Procysbi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10143665	HORIZON PHARMA USA	Methods for storing cysteamine formulations and related methods of treatment	Aug, 2036 (13 years from now)
US10328037	HORIZON PHARMA USA	Methods for storing cysteamine formulations and related methods of treatment	Aug, 2036 (13 years from now)
US10548859	HORIZON PHARMA USA	Methods for storing Cysteamine formulations and related methods of treatment	Aug, 2036 (13 years from now)
US10905662	HORIZON PHARMA USA	Methods for storing cysteamine formulations and related methods of treatment	Aug, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 22, 2024
Pediatric Exclusivity (PED)	Feb 14, 2023

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 14 February, 2020

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: GRANULE, DELAYED RELEASE;ORAL

68. List of Rinvoq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9951080	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10981923	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11186584	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11512092	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10344036	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10730883	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11198697	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10519164	ABBVIE INC	Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10597400	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10995095	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10550126	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10981924	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US9963459	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof	Oct, 2036 (13 years from now)
US11365198	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US10202393	ABBVIE INC	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 14, 2024
New Chemical Entity Exclusivity (NCE)	Aug 16, 2024

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable

Dosage: TABLET, EXTENDED RELEASE;ORAL

69. List of Symjepi drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11141540	ADAMIS PHARMS CORP	Syringe devices	Oct, 2036 (13 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 15 June, 2017

Treatment: A method for administering a therapeutic dose of epinephrine

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

70. List of Tascenso Odt drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10925829	HANDA	Stable solid fingolimod dosage forms	Jan, 2036 (12 years from now)
US9925138	HANDA	Stable solid fingolimod dosage forms	Jan, 2036 (12 years from now)
US10555902	HANDA	Stable fingolimod dosage forms	Jan, 2036 (12 years from now)

Drugs and Companies using FINGOLIMOD LAURYL SULFATE ingredient

Market Authorisation Date: 23 December, 2021

Treatment: Treatment of multiple sclerosis in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

71. List of Tibsovo drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653710	SERVIER	Combination therapy for treating malignancies	Oct, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 20, 2023
Orphan Drug Exclusivity (ODE)	Aug 25, 2028
New Indication (I)	May 25, 2025

Drugs and Companies using IVOSIDENIB ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 20 July, 2018

Treatment: A method for treating newly diagnosed aml characterized by the presence of a mutant allele of idh1 selected from r132h, r132c, r132l, r132v, r132s and r132gf by administering ivosidenib and azacitidine

Dosage: TABLET;ORAL

72. List of Trudhesa drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266799	IMPEL NEUROPHARMA	In-line nasal delivery device	Nov, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Sep 2, 2024

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Market Authorisation Date: 02 September, 2021

Treatment: NA

Dosage: SPRAY, METERED;NASAL

73. List of Turalio drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9802932	DAIICHI SANKYO INC	Solid forms of a compound modulating kinases	May, 2036 (13 years from now)
US10730876	DAIICHI SANKYO INC	Synthesis of a compound that modulates kinases	May, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10189833	DAIICHI SANKYO INC	Solid forms of a compound modulating kinases	May, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 2, 2024
Orphan Drug Exclusivity (ODE)	Aug 2, 2026

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 02 August, 2019

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

74. List of Uptravi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828298	ACTELION	Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide	Dec, 2036 (13 years from now)
US10821108	ACTELION	Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide	Dec, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 21, 2022

Drugs and Companies using SELEXIPAG ingredient

Market Authorisation Date: 21 December, 2015

Treatment: Method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag

Dosage: TABLET;ORAL

75. List of Veklury drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11382926	GILEAD SCIENCES INC	Methods for treating Arenaviridae and Coronaviridae virus infections	Sep, 2036 (13 years from now)
US10695361	GILEAD SCIENCES INC	Methods for treating arenaviridae and coronaviridae virus infections	Sep, 2036 (13 years from now)
US11007208	GILEAD SCIENCES INC	Methods for treating arenaviridae and coronaviridae virus infections	Sep, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 22, 2025
New Patient Population (NPP)	Apr 25, 2025
New Dosing Schedule (D)	Jan 21, 2025

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg)

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

76. List of Vitrakvi drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10799505	BAYER HEALTHCARE	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	Aug, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 26, 2025
New Chemical Entity Exclusivity (NCE)	Nov 26, 2023

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: NA

Dosage: SOLUTION;ORAL

77. List of Vitrakvi drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10799505	BAYER HLTHCARE	Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate	Aug, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 26, 2025
New Chemical Entity Exclusivity (NCE)	Nov 26, 2023

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 26 November, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

78. List of Vivjoa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9840492	MYCOVIA PHARMS	Antifungal compounds and processes for making	Mar, 2036 (13 years from now)
US10414751	MYCOVIA PHARMS	Antifungal compounds and processes for making	Mar, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 26, 2027
Generating Antibiotic Incentives Now (GAIN)	Apr 26, 2032

Drugs and Companies using OTESECONAZOLE ingredient

NCE-1 date: April, 2031

Market Authorisation Date: 26 April, 2022

Treatment: NA

Dosage: CAPSULE;ORAL

79. List of Voxzogo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9907834	BIOMARIN PHARM	Use of C-type natriuretic peptide variants to treat skeletal dysplasia	Aug, 2036 (13 years from now)
US10646550	BIOMARIN PHARM	Use of C-type natriuretic peptide variants to treat skeletal dysplasia	Aug, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 19, 2026

Drugs and Companies using VOSORITIDE ingredient

NCE-1 date: November, 2025

Market Authorisation Date: 19 November, 2021

Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses

Dosage: POWDER;SUBCUTANEOUS

80. List of Vtama drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458108	DERMAVANT SCI	NA	May, 2036 (13 years from now)
US10195160	DERMAVANT SCI	Topical pharmaceutical compositions	May, 2036 (13 years from now)
US10426743	DERMAVANT SCI	Topical pharmaceutical compositions	May, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 23 May, 2022

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: CREAM;TOPICAL

81. List of Xaciato drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129896	DARE	Topical formulations and treatments	Sep, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Dec 7, 2024
Generating Antibiotic Incentives Now (GAIN)	Dec 7, 2029

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 07 December, 2021

Treatment: Method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation

Dosage: GEL;VAGINAL

82. List of Xofluza drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10392406	GENENTECH INC	Substituted polycyclic pyridone derivatives and prodrugs thereof	Apr, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10633397	GENENTECH INC	Substituted polycyclic pyridone derivatives and prodrugs thereof	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Oct 16, 2022
New Chemical Entity Exclusivity (NCE)	Oct 24, 2023

Drugs and Companies using BALOXAVIR MARBOXIL ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 24 October, 2018

Treatment: Method for treating influenza; Method for post-exposure prophylaxis of influenza

Dosage: TABLET;ORAL

83. List of Xospata drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10786500	ASTELLAS	Stable pharmaceutical composition for oral administration	Jul, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 28, 2025
New Chemical Entity Exclusivity (NCE)	Nov 28, 2023

Drugs and Companies using GILTERITINIB FUMARATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

84. List of Xtampza Er drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646485	COLLEGIUM PHARM INC	Process of making stable abuse-deterrent oral formulations	Sep, 2036 (13 years from now)
US10188644	COLLEGIUM PHARM INC	Process of making stable abuse-deterrent oral formulations	Sep, 2036 (13 years from now)
US9737530	COLLEGIUM PHARM INC	Process of making stable abuse-deterrent oral formulations	Sep, 2036 (13 years from now)
US9968598	COLLEGIUM PHARM INC	Process of making stable abuse-deterrent oral formulations	Sep, 2036 (13 years from now)

Drugs and Companies using OXYCODONE ingredient

Market Authorisation Date: 26 April, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

85. List of Xyosted (autoinjector) drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9950125	ANTARES PHARMA INC	Needle assisted jet injection administration of testosterone compositions	Sep, 2036 (13 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

86. List of Zembrace Symtouch drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537554	UPSHER SMITH LABS	Pharmaceutical composition for treating migraine	Jan, 2036 (12 years from now)
US11364224	UPSHER SMITH LABS	Pharmaceutical composition for treating migraine	Jan, 2036 (12 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 28 January, 2016

Treatment: Treatment of migraine

Dosage: SOLUTION;SUBCUTANEOUS

87. List of Zuragard drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9844654	ZUREX PHARMA	Medical skin applicator apparatus	Apr, 2036 (13 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Apr 26, 2022
M	Jun 24, 2024

Drugs and Companies using ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 26 April, 2019

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SOLUTION;TOPICAL

availability in other generic markets.

Click on the highlighted region to filter.

List of large molecules

1. List of Tysabri large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US10844416	BIOGEN INC.	Manganese supplementation for control of glycosylation in mammalian cell culture process	Jan, 2036 (12 years from now)
US11268119	BIOGEN INC.	Copper supplementation for control of glycosylation in mammalian cell culture process	Feb, 2036 (13 years from now)

Ingredients: NATALIZUMAB

2. List of Eylea large molecules

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
US10927342	REGENERON PHARMACEUTICALS, INC.	Taurine supplemented cell culture medium and methods of use	Aug, 2036 (13 years from now)
USD934069	REGENERON PHARMACEUTICALS, INC.	Packaging	Oct, 2036 (13 years from now)

Ingredients: AFLIBERCEPT

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in

Drugs expiring in 2037

Drugs made by Bausch And Lomb Inc

Strength	Dosage	Availability
EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Dosage	Availability
24MG;26MG	TABLET;ORAL	Prescription
49MG;51MG	TABLET;ORAL	Prescription
97MG;103MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
EQ 5MG BASE	CAPSULE;ORAL	Prescription
EQ 10MG BASE	CAPSULE;ORAL	Prescription
EQ 20MG BASE	CAPSULE;ORAL	Prescription
EQ 40MG BASE	CAPSULE;ORAL	Prescription

Strength	Dosage	Availability
0.5MG/0.1ML (0.5MG/0.1ML)	SOLUTION;SUBCUTANEOUS	Prescription
1MG/0.2ML (1MG/0.2ML)	SOLUTION;SUBCUTANEOUS	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
75 mg, 100 mg and 125 mg	04 Feb, 2019	12		22 Jan, 2023
75 mg, 100 mg and 125 mg	24 Nov, 2020	1		28 Feb, 2034

Strength	Dosage	Availability
75MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription
125MG	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
70 mg	14 Dec, 2018	1	31 Mar, 2021	30 Oct, 2033	Eligible
140 mg	13 Nov, 2017	8	31 Mar, 2021	24 Oct, 2034	Deferred
140 mg and 560 mg	05 Nov, 2018	1		03 Mar, 2036
280 mg and 420 mg	14 Dec, 2018	1		03 Mar, 2036

Strength	Dosage	Availability
140MG	TABLET;ORAL	Prescription
280MG	TABLET;ORAL	Prescription
420MG	TABLET;ORAL	Prescription
560MG	TABLET;ORAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
40 mg and 80 mg	12 Apr, 2021	4		10 Aug, 2040
60 mg	14 Feb, 2022	1		10 Aug, 2040

Strength	Dosage	Availability
100PPM	GAS;INHALATION	Discontinued
800PPM	GAS;INHALATION	Prescription

Strength	Submission Date	ANDA(s) Filed	Last patent expiry
546 mg/1.75 mL	24 Jun, 2020	1	05 Apr, 2036
819 mg/2.625 mL	30 Apr, 2021	1	05 Apr, 2036
273 mg/0.875 mL and 410 mg/1.315 mL	14 Jul, 2021	1	05 Apr, 2036

Strength	Dosage	Availability
1.092GM/3.5ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
1.560GM/5ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
273MG/0.875ML (273MG/0.875ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
410MG/1.315ML (311.79MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
546MG/1.75ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
819MG/2.625ML (312MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

Strength	Dosage	Availability
10MG	FILM;SUBLINGUAL	Prescription
15MG	FILM;SUBLINGUAL	Prescription
20MG	FILM;SUBLINGUAL	Prescription
25MG	FILM;SUBLINGUAL	Prescription
30MG	FILM;SUBLINGUAL	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mcg/vial and 500 mcg/vial	14 Apr, 2015	2	29 Jun, 2016	03 Oct, 2032	Eligible
200 mcg/vial	01 May, 2015	1	07 Dec, 2015	03 Oct, 2032	Deferred

Strength	Dosage	Availability
100MCG/5ML (20MCG/ML)	SOLUTION;INTRAVENOUS	Prescription
200MCG/5ML (40MCG/ML)	SOLUTION;INTRAVENOUS	Prescription
500MCG/5ML (100MCG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Dosage	Availability
1250MG/5ML (250MG/ML)	SOLUTION;INTRAMUSCULAR	Prescription
250MG/ML (250MG/ML)	SOLUTION;INTRAMUSCULAR	Prescription
275MG/1.1ML (250MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

Strength	Dosage	Availability
EQ 105MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 135MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
2.5MG/0.5ML (2.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
5MG/0.5ML (5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
7.5MG/0.5ML (7.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
10MG/0.5ML (10MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
12.5MG/0.5ML (12.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
15MG/0.5ML (15MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription
EQ 200MG BASE	TABLET;ORAL	Prescription

Strength	Dosage	Availability
6MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
9MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Pharsight

Drug Patents Expiring in 2036

1. List of Airduo Digihaler drug patents

2. List of Amvuttra drug patents

3. List of Armonair Digihaler drug patents

4. List of Austedo drug patents

5. List of Balversa drug patents

6. List of Baqsimi drug patents

7. List of Biktarvy drug patents

8. List of Brilinta drug patents

9. List of Calquence drug patents

10. List of Calquence drug patents

11. List of Carospir drug patents

12. List of Cotellic drug patents

13. List of Cyclophosphamide drug patents

14. List of Cysview Kit drug patents

15. List of Daurismo drug patents

16. List of Delstrigo drug patents

17. List of Dexmedetomidine Hydrochloride drug patents

18. List of Duobrii drug patents

19. List of Elyxyb drug patents

20. List of Entresto drug patents

21. List of Epaned drug patents

22. List of Esomeprazole Magnesium drug patents

23. List of Exem Foam Kit drug patents

24. List of Ezallor Sprinkle drug patents

25. List of Fintepla drug patents

26. List of Fyarro drug patents

27. List of Gavreto drug patents

28. List of Genosyl drug patents

29. List of Gloperba drug patents

30. List of Gvoke Hypopen drug patents

31. List of Ibrance drug patents

32. List of Imbruvica drug patents

33. List of Ingrezza drug patents

34. List of Inomax drug patents

35. List of Invega Hafyera drug patents

36. List of Kisqali drug patents

37. List of Kisqali Femara Co-pack (copackaged) drug patents

38. List of Korlym drug patents

39. List of Kynmobi drug patents

40. List of Lansoprazole drug patents

41. List of Leqvio drug patents

42. List of Levothyroxine Sodium drug patents

43. List of Levothyroxine Sodium drug patents

44. List of Lexette drug patents

45. List of Lonhala Magnair Kit drug patents

46. List of Lorbrena drug patents

47. List of Lotemax Sm drug patents

48. List of Lytgobi drug patents

49. List of Makena drug patents

50. List of Mavyret drug patents

51. List of Minolira drug patents

52. List of Mounjaro drug patents

53. List of Mycapssa drug patents

54. List of Myrbetriq Granules drug patents

55. List of Nexlizet drug patents

56. List of Nubeqa drug patents

57. List of Ocaliva drug patents

58. List of Odomzo drug patents

59. List of Omeprazole drug patents

60. List of Onivyde drug patents

61. List of Orgovyx drug patents

62. List of Orilissa drug patents

63. List of Ortikos drug patents

64. List of Oxbryta drug patents

65. List of Proair Digihaler drug patents

66. List of Procysbi drug patents

67. List of Procysbi drug patents

68. List of Rinvoq drug patents

69. List of Symjepi drug patents

70. List of Tascenso Odt drug patents

71. List of Tibsovo drug patents

72. List of Trudhesa drug patents

73. List of Turalio drug patents

74. List of Uptravi drug patents

75. List of Veklury drug patents

76. List of Vitrakvi drug patents

77. List of Vitrakvi drug patents

78. List of Vivjoa drug patents

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg and 75 mg	11 May, 2020	1		16 Aug, 2036
75 mg/Packet and 300 mg/Packet	16 Dec, 2021	1		16 Aug, 2036

Strength	Dosage	Availability
EQ 25MG BASE	CAPSULE, DELAYED RELEASE;ORAL	Prescription
EQ 75MG BASE	CAPSULE, DELAYED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
EQ 75MG BASE/PACKET	GRANULE, DELAYED RELEASE;ORAL	Prescription
EQ 300MG BASE/PACKET	GRANULE, DELAYED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
0.15MG/0.3ML (0.15MG/0.3ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription
0.3MG/0.3ML (0.3MG/0.3ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Prescription

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1 mg, 1.2 mg, 1.4 mg and 1.6 mg	23 Dec, 2019	4	21 Dec, 2022	01 Aug, 2030	Eligible
1.8 mg/vial	29 Jul, 2022	1		01 Aug, 2030

Strength	Dosage	Availability
0.2MG	TABLET;ORAL	Prescription
0.4MG	TABLET;ORAL	Prescription
0.6MG	TABLET;ORAL	Prescription
0.8MG	TABLET;ORAL	Prescription
1MG	TABLET;ORAL	Prescription
1.2MG	TABLET;ORAL	Prescription
1.4MG	TABLET;ORAL	Prescription
1.6MG	TABLET;ORAL	Prescription

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription
100MG/20ML (5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

Strength	Dosage	Availability
0.4MG/VIAL	POWDER;SUBCUTANEOUS	Prescription
0.56MG/VIAL	POWDER;SUBCUTANEOUS	Prescription
1.2MG/VIAL	POWDER;SUBCUTANEOUS	Prescription

Strength	Dosage	Availability
9MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
13.5MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
18MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
27MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
36MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Strength	Dosage	Availability
50MG/0.5ML (50MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
75MG/0.5ML (75MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
100MG/0.5ML (100MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription